TABLE 1

Characteristics of healthy adult subjects receiving meropenem and RPX7009

Subject categoryNo. of male subjects (%)Mean ± SD
Age (yr)Ht (cm)Wt (kg)CLCR (ml/min)aTotal cell count in BAL fluid (cells/mm3)Macrophages (%)
All subjects (n = 25)18 (72)39.0 ± 10.6173.9 ± 9.580.3 ± 9.493.9 ± 22.8141.1 ± 100.885.4 ± 9.2
BAL sampling time (h)b
    1.55 (100)32.2 ± 8.9180.9 ± 7.083.2 ± 5.5113.1 ± 12.5113.6 ± 46.389.4 ± 7.0
    3.253 (60)39.6 ± 11.5173.6 ± 10.380.5 ± 11.986.5 ± 15.192.2 ± 52.382.6 ± 13.1
    45 (100)40.4 ± 9.4178.6 ± 10.180.8 ± 13105.7 ± 34.8172.6 ± 80.491.0 ± 4.0
    63 (60)43.0 ± 12.4168.5 ± 9.180.9 ± 8.384.8 ± 19.5197.2 ± 186.179.6 ± 9.7
    82 (40)39.8 ± 11.8168.1 ± 5.276.2 ± 9.279.3 ± 8.9129.8 ± 76.084.6 ± 7.9
  • a CLCR, calculated creatinine clearance.

  • b n = 5 at each bronchoalveolar lavage (BAL) sampling time.